NSE ABBOTINDIA · BSE 500488 · Biotechnology & Drugs · NIFTY 500
Abbott India Share Price
₹26,930.00
▲ +₹32.28 · 0.12%
NSE · as of 24 Sep 2026, 9:59 AM · BSE ₹26,980.00
Today's range
₹26,769.65Low₹27,225.00High
52-week range
₹25,049.28Low · 24 Apr 2026₹30,530.62High · 25 Nov 2025
Abbott India Overview
Where the price stands, how it has moved and how it sits against its averages.
Abbott India shares last traded at ₹26,930.00 on the NSE, up 0.12% on the day. That is 11.8% below the 52-week high of ₹30,530.62 and 7.5% above the 52-week low of ₹25,049.28. The stock trades at 33.33× earnings, below the sector average of 36.50. Its market value is ₹57,457 Cr.
Price returns
1 Day▲ +0.12%
5 Days▲ +3.10%
This month▲ +4.20%
3 Months▲ +5.72%
6 Months▲ +2.48%
This year▼ −6.78%
1 Year▼ −10.48%
Against the market: 1 Month ▲ +5.02% · 3 Months ▲ +8.77% · 6 Months ▲ +3.08% · This year ▲ +6.17% · 1 Year ▼ −1.77%
Shading grows with the size of the move. Prices refresh every 15 minutes while the market is open (9:15 AM–3:30 PM IST); next update from Mon 28 Sep, 9:15 AM.
Moving averages — price is above 5 of 6
- 50-day average₹27,034.98 ▼ price 0.4% below
- Today's price₹26,930.00
- 300-day average₹26,901.08 ▲ price 0.1% above
- 100-day average₹26,702.02 ▲ price 0.9% above
- 5-day average₹26,698.00 ▲ price 0.9% above
- 20-day average₹26,158.00 ▲ price 3.0% above
- 10-day average₹26,120.50 ▲ price 3.1% above
Averages above today's price sit higher on the ladder. Price above most of its averages is usually read as an upward trend.
Abbott India Financial Results
Revenue and net profit in ₹ crore, with the full statements underneath.
6,929
1,552
Year by year
| Fiscal year | Revenue | Growth | Net profit | Net margin | EPS | Dividend |
|---|---|---|---|---|---|---|
| FY 2026 | ₹6,929 Cr | ▲ +8.1% | ₹1,552 Cr | 22.4% | ₹730.39 | ₹525.00 |
| FY 2025 | ₹6,409 Cr | ▲ +9.6% | ₹1,414 Cr | 22.1% | ₹665.64 | ₹475.00 |
| FY 2024 | ₹5,849 Cr | ▲ +9.4% | ₹1,201 Cr | 20.5% | ₹565.30 | ₹410.00 |
| FY 2023 | ₹5,349 Cr | ▲ +8.7% | ₹949 Cr | 17.8% | ₹446.80 | ₹180.00 |
| FY 2022 | ₹4,919 Cr | ▲ +14.1% | ₹799 Cr | 16.2% | ₹375.87 | ₹145.00 |
| FY 2021 | ₹4,310 Cr | ▲ +5.3% | ₹691 Cr | 16.0% | ₹325.04 | ₹120.00 |
| FY 2020 | ₹4,093 Cr | — | ₹593 Cr | 14.5% | ₹279.04 | ₹107.00 |
1,814
429
Quarter by quarter
| Quarter | Revenue | vs prev. qtr | Net profit | Net margin | EPS |
|---|---|---|---|---|---|
| Q1 FY27 | ₹1,814 Cr | ▲ +6.1% | ₹429 Cr | 23.6% | ₹201.66 |
| Q4 FY26 | ₹1,710 Cr | ▼ −0.8% | ₹395 Cr | 23.1% | ₹185.88 |
| Q3 FY26 | ₹1,724 Cr | ▼ −1.9% | ₹376 Cr | 21.8% | ₹176.92 |
| Q2 FY26 | ₹1,757 Cr | ▲ +1.1% | ₹415 Cr | 23.6% | ₹195.42 |
| Q1 FY26 | ₹1,738 Cr | ▲ +8.3% | ₹366 Cr | 21.0% | ₹172.17 |
| Q4 FY25 | ₹1,605 Cr | ▼ −0.6% | ₹367 Cr | 22.9% | ₹172.75 |
| Q3 FY25 | ₹1,614 Cr | ▼ −1.1% | ₹361 Cr | 22.3% | ₹169.78 |
| Q2 FY25 | ₹1,633 Cr | — | ₹359 Cr | 22.0% | ₹168.76 |
Balance sheet — FY26
Owes (liabilities)Shareholders' equity
27%
73%
- Total assets₹6,502 Cr
- Total liabilities₹1,728 Cr
- Shareholders' equity₹4,774 Cr
- Total debt₹172 Cr
- Cash & investments₹2,232 Cr
- Current ratio2.55×
- Revenue growth, 5 yr9.96% a year
- EPS growth, 5 yr17.58% a year
- Operating margin (TTM)27.02%
- Net margin (TTM)23.05%
Cash flow — FY26
Operating activities
▲ ₹1,319 Cr
Investing activities
▼ −₹371 Cr
Financing activities
▼ −₹1,066 Cr
Free cash flow
▲ ₹1,278 Cr
Net change in cash
▼ −₹118 Cr
Right of the line = cash coming in, left = cash going out. Free cash flow = cash from operations minus capital spending.
Full financial statements, FY20–FY26
| ₹ crore | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|
| Total revenue | 4,093.14 | 4,310.02 | 4,919.27 | 5,348.73 | 5,848.91 | 6,409.15 | 6,929.05 |
| Cost of revenue | 2,338.20 | 2,410.81 | 2,682.09 | 3,001.12 | 3,248.98 | 3,526.47 | 3,720.26 |
| Gross profit | 1,754.95 | 1,899.21 | 2,237.18 | 2,347.61 | 2,599.93 | 2,882.68 | 3,208.79 |
| Operating expenses | 3,386.48 | 3,441.50 | 3,892.34 | 4,206.75 | 4,463.28 | 4,781.30 | 5,111.62 |
| Operating income | 706.66 | 868.52 | 1,026.93 | 1,141.98 | 1,385.63 | 1,627.85 | 1,817.43 |
| Depreciation | 59.61 | 58.13 | 66.10 | 69.97 | 71.17 | 71.80 | 75.96 |
| Profit before tax | 802.69 | 925.95 | 1,079.73 | 1,273.82 | 1,617.75 | 1,886.95 | 2,079.27 |
| Tax | 209.76 | 235.26 | 281.03 | 324.41 | 416.53 | 472.51 | 527.25 |
| Net profit | 592.93 | 690.69 | 798.70 | 949.41 | 1,201.22 | 1,414.44 | 1,552.02 |
| EPS (₹) | 279.04 | 325.04 | 375.87 | 446.80 | 565.30 | 665.64 | 730.39 |
| Dividend per share (₹) | 107.00 | 120.00 | 145.00 | 180.00 | 410.00 | 475.00 | 525.00 |
| ₹ crore | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|
| Total assets | 3,546.85 | 3,840.45 | 4,224.12 | 4,555.51 | 5,193.49 | 5,917.31 | 6,501.93 |
| Current assets | 3,204.64 | 3,487.41 | 3,853.04 | 3,025.11 | 3,245.84 | 4,765.11 | 3,770.69 |
| Cash & short-term investments | 2,191.81 | 2,466.75 | 2,737.54 | 1,924.32 | 2,119.71 | 3,114.90 | 2,232.33 |
| Inventory | 545.98 | 717.59 | 687.82 | 648.85 | 619.58 | 882.04 | 947.26 |
| Property, plant & equipment | 270.57 | 250.27 | 263.03 | 233.05 | 228.39 | 347.60 | 333.05 |
| Total liabilities | 1,115.14 | 1,238.29 | 1,404.33 | 1,366.97 | 1,494.60 | 1,684.16 | 1,727.74 |
| Current liabilities | 891.10 | 1,030.86 | 1,203.19 | 1,206.02 | 1,342.72 | 1,407.19 | 1,476.57 |
| Total debt | 174.89 | 152.58 | 151.69 | 113.17 | 83.23 | 196.67 | 171.99 |
| Total equity | 2,431.71 | 2,602.16 | 2,819.79 | 3,188.54 | 3,698.89 | 4,233.15 | 4,774.19 |
| ₹ crore | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|
| From operations | 626.11 | 726.74 | 947.66 | 893.39 | 1,212.81 | 1,011.84 | 1,319.24 |
| From investing | −401.19 | −71.82 | −395.84 | −147.71 | −416.03 | 182.18 | −371.38 |
| From financing | −216.79 | −581.79 | −637.38 | −638.72 | −744.71 | −925.17 | −1,066.12 |
| Capital expenditure | −15.73 | −23.31 | −44.07 | −34.11 | −48.33 | −52.60 | −40.92 |
| Dividends paid | −138.12 | −531.23 | −584.36 | −584.36 | −690.60 | −871.22 | −1,009.34 |
| Net change in cash | 8.13 | 73.13 | −85.56 | 106.96 | 52.07 | 268.85 | −118.26 |
What Analysts Say
7 analysts
Recommendations from 7 analysts who cover Abbott India.
Strong Buy
average rating 1.57 on a 1–5 scale
Strong buyBuyHoldSellStrong sell
▲ 6 bullish (85.7%) · 1 hold (14.3%) · ▼ 0 bearish (0.0%)
Votes
Strong Buy
4 (57%)
Buy
2 (29%)
Hold
1 (14%)
Sell
0 (0%)
Strong Sell
0 (0%)
How the votes changed
| Rating | 3M ago | 2M ago | 1M ago | 1W ago | Now | 3-month change |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | — |
| Buy | 2 | 2 | 2 | 2 | 2 | — |
| Hold | 1 | 1 | 1 | 1 | 1 | — |
| Sell | 0 | 0 | 0 | 0 | 0 | — |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | — |
Analyst ratings are opinions, not a guarantee of returns.
Abbott India vs Peers
Side by side with other biotechnology & drugs companies. The small bars compare each column.
| Company | Price | Change | Market cap | P/E | P/B | ROE (5 yr) | Net margin | Div. yield | Rating |
|---|---|---|---|---|---|---|---|---|---|
| Abbott India | ₹26,930.00 | ▲ +0.12% | ₹57,457 Cr | 33.33 | 11.99 | 33.56% | 23.05% | 1.95% | This stock |
| Sun Pharmaceutical Industries | ₹1,853.00 | ▼ −0.64% | ₹4,44,586 Cr | 38.40 | 5.55 | 14.22% | 19.12% | 0.83% | Moderately Bearish |
| Divi's Laboratories | ₹9,613.00 | ▲ +0.17% | ₹2,55,195 Cr | 73.32 | 11.48 | 16.87% | 24.32% | 0.41% | Bullish |
| Torrent Pharmaceuticals | ₹4,935.00 | ▼ −0.90% | ₹1,87,705 Cr | 72.73 | 19.22 | 23.00% | 15.29% | 0.80% | Bullish |
| Cipla | ₹1,404.00 | ▲ +1.74% | ₹1,13,423 Cr | 27.57 | 3.33 | 14.47% | 13.74% | 0.92% | Neutral |
| Zydus Lifesciences | ₹1,180.00 | ▲ +0.90% | ₹1,17,705 Cr | 21.19 | 4.24 | 17.90% | 18.51% | 0.09% | Bullish |
Rating = the data provider's overall technical view of each peer. Company names link to their own pages.
Abbott India Key Metrics
Each ratio placed against a benchmark — the sector average, the company's own 5-year average, or a common rule of thumb.
Abbott IndiaBenchmarkComfortable → stretched
Valuation Is the price reasonable?
P/E (TTM)Price ÷ yearly earnings per share
33.33
▼ 9% below the sector average of 36.50
P/E, 12-month rangeLow 33.33 · high 59.72
0%
Today's P/E sits 0% of the way from its low to its high
P/BPrice ÷ book value per share
11.99
P/SPrice ÷ sales per share
8.17
P/CFPrice ÷ cash flow per share
33.85
PEGP/E ÷ earnings growth (≈1 is fair)
1.99
Profitability Of every ₹100 of sales, how much is kept?
Gross marginKept after the cost of goods
47.43%
▲ above its 5-yr average of 45.07%
Operating marginKept after running costs
27.02%
▲ above its 5-yr average of 23.76%
Pre-tax marginKept before tax
30.81%
▲ above its 5-yr average of 26.95%
Net marginKept as profit
23.05%
▲ above its 5-yr average of 20.08%
Returns & efficiency How well does it use its money?
Return on equityProfit on shareholders' money
34.46%
▲ above its 5-yr average of 33.56%
Return on assetsProfit on everything it owns
24.99%
▲ above its 5-yr average of 23.60%
Return on investmentProfit on long-term capital
32.55%
▲ above its 5-yr average of 31.72%
Growth Is the business getting bigger?
Revenue — last 12 months
+6.3%
▲ growing
Revenue — 3 yr, a year
+9.0%
▲ growing
Revenue — 5 yr, a year
+10.0%
▲ growing
EPS — last 12 months
+11.2%
▲ growing
EPS — 3 yr, a year
+17.8%
▲ growing
EPS — 5 yr, a year
+17.6%
▲ growing
Dividend — 3 yr, a year
+42.9%
▲ growing (off the scale)
Book value — 5 yr, a year
+12.9%
▲ growing
Financial strength Can it pay its bills and debts?
Debt to equityBorrowings for every ₹1 of shareholders' money
0.04×
Current ratioShort-term assets for every ₹1 due within a year
2.55×
Quick ratioLike the current ratio, without inventory
1.91×
Interest coverOperating profit ÷ interest to pay
76.19×
Payout ratioShare of profit paid as dividend
89.82%
Per share What each share stands for
EPS (TTM)
₹759.88
Book value
₹2,251.98
Cash flow
₹795.75
Dividend
₹525.00
Revenue
₹3,296.30
The share price is 11.96× the book value behind each share.
Benchmarks: sector averages and 5-year averages come from the data provider; the debt and liquidity bands are common rules of thumb, not investment advice.
All 111 metrics from the data provider
Valuation
P/E excluding extraordinary items, most recent fiscal year36.88
Current Dividend Yield - Common Stock Primary Issue, LTM1.95
Price to Book - most recent fiscal year11.99
P/E Basic excluding extraordinary items - TTM33.33
P/E including extraordinary items - TTM35.45
P/E excluding extraordinary items low, trailing 12 months33.33
Price to Tangible Book - most fiscal year12.00
Dividend Yield - 5 Year Average1.42
Price to sales - most recent fiscal year8.26
Dividend Yield - indicated annual dividend divided by closing price1.95
Price to Cash Flow per share - trailing 12 month33.85
Peg Ratio1.99
Price to Free Cash Flow per Share - most recent fiscal year212.79
P/E Normalized, most recent fiscal year36.63
P/E excluding extraordinary items high, trailing 12 months59.72
P/E excluding extraordinary items, most recent fiscal year quarter35.45
Price to sales - trailing 12 month8.17
Net Debt, LFY−20,603.40
Per share
Dividend Per Share - 5 year average347.00
Cash Flow per share - trailing 12 month795.75
Cash Flow per share - most recent fiscal year766.13
EPS including extraordinary items - trailing 12 month759.88
EPS including extraordinary items - most recent fiscal year730.39
EBITD per share - trailing 12 month935.14
Revenue/share - trailing 12 month3,296.30
EPS excluding extraordinary items - trailing 12 month759.88
EPS Basic excluding extraordinary items - most recent fiscal year730.39
EPS Basic excluding extraordinary items - trailing 12 month759.88
Book value per share - most recent fiscal year2,246.75
Dividend per share - most recent fiscal year525.00
Revenue/share - most recent fiscal year3,260.84
EPS Normalized - most recent fiscal year735.34
Book value (tangible) per share - most recent fiscal year2,244.97
Dividends per share - trailing 12 month525.00
EPS excluding extraordinary items - most recent fiscal year730.39
Cash per share - most recent fiscal year1,050.54
Margins
Operating margin - trailing 12 month27.02
Gross Margin - 5 year average45.07
Operating margin - 1st historical fiscal year26.23
Operating Margin - 5 year average23.76
Net Profit Margin % - 1st historical fiscal year22.40
Gross Margin - 1st historical fiscal year46.31
Net Profit Margin % - trailing 12 month23.05
Net Profit Margin - 5 year average20.08
Pretax Margin - 5 year average26.95
Pretax margin - 1st historical fiscal year30.01
Pretax margin - trailing 12 month30.81
Free Operating Cash Flow/Revenue, 5 Year Average4.84
Gross Margin - trailing 12 month47.43
Growth
EPS Change %, TTM over TTM11.18
Revenue growth rate, 5 year9.96
EPS growth rate, 5 year17.58
Revenue Change % - most recent quarter 1 year ago4.33
Growth rate% - dividend, 3 year42.88
Growth rate% - EPS, 3 year17.80
Revenue/share (5 yr growth)9.96
Free Operating Cash Flow, 5 Year CAGR9.33
Tangible Book Value, Total Equity, 5 Year CAGR12.90
Earnings Before Interest, Taxes, Depreciation & Amortization, 5 Year Interim CAGR15.83
Capital Spending growth rate, 5 year11.91
Revenue Change %, TTM over TTM6.29
Growth rate% - Revenue, 3 year9.01
Book value per share growth rate, 5 year12.90
EPS Change % - most recent quarter 1 year ago17.13
Net Profit Margin growth rate, 5 year6.93
Earnings Before Interest, Taxes, Depreciation & Amortization, 5 Year CAGR15.58
Total Debt, 5 Year CAGR2.42
Financial strength
Free Cash Flow - most recent fiscal year2,689.80
LT debt/equity - most recent fiscal year0.03
Quick ratio - most recent fiscal year1.91
Payout ratio - trailing 12 month86.33
Current ratio - most recent fiscal year2.55
Current EV/Free Cash Flow, LFY95.50
Total debt/total equity - most recent fiscal year0.04
Net Interest coverage - trailing 12 month76.19
Payout ratio - most recent fiscal year89.82
Returns & efficiency
Return on average equity - 5 year average33.56
Net Income/employee - trailing 12 month43,88,910.00
Revenue/employee - most recent fiscal year1,88,85,390.00
Return on investment - most recent fiscal year32.55
Return on average assets - most recent fiscal year24.99
Receivables turnover - most recent fiscal year13.89
Inventory turnover - most recent fiscal year4.07
Revenue/employee - trailing 12 month1,90,38,810.00
Return on average assets - 5 year average23.60
Net Income/employee - most recent fiscal year42,30,090.00
Asset turnover - most recent fiscal year1.12
Return on average equity - most recent fiscal year34.46
Return on investment - 5 year average31.72
Price & volume
Market Cap57,064.92
52 week Low Date24 Apr 2026
Price - 1 Day % Change−1.07
Relative (S&P500) price percent change - 13 week8.77
Avg trading volume last 10 days0.01
Price - 13 week price percent change5.72
Price - 52 week price percent change−10.48
Avg Trading Volume Last 3 months0.23
Price - 5 Day % Change3.10
Price % Change Month To Date4.20
Relative (S&P500) price percent change - 04 week5.02
52 week High Date25 Nov 2025
Price - 26 week price percent change2.48
PDATE23 Sep 2026
Price - YTD price percent change−6.78
Relative (S&P500) price percent change - 52 week−1.77
NPRICE26,935.00
Relative (S&P500) price percent change - 26 week3.08
52 week Low25,035.17
52 week High30,515.03
Beta0.12
Relative (S&P500) price percent change - Year to Date6.17
Dividends & Corporate Events
Payouts to shareholders, splits and bonus issues, and company meetings — newest first.
₹525.00
- Dividend yield1.95%
- Payout ratio89.82%
- 5-year average dividend₹347.00 a share
- Latest dividend₹525.00 per share · 24 Jul 2026
Corporate calendar
- MeetingAnnual General Meeting
- MeetingAnnual General Meeting
- BoardQuarterly Results
- Dividend₹525.00 per share · 5,250% · Final dividend
- Dividend₹131.00 per share · 1,310% · Special special dividend
- MeetingPostal Ballot
- BoardAudited Results & Final Dividend
- MeetingPostal Ballot
Show 14 older events
- BoardQuarterly Results
- BoardQuarterly Results
- MeetingAnnual General Meeting
- BoardQuarterly Results
- Dividend₹475.00 per share · 4,750% · Final dividend
- BoardAudited Results & Final Dividend
- BoardQuarterly Results
- BoardQuarterly Results
- MeetingAnnual General Meeting
- Dividend₹410.00 per share · 4,100% · Final dividend
- Dividend₹180.00 per share · 1,800% · Final dividend
- Dividend₹145.00 per share · 1,450% · Special special dividend
- Dividend₹145.00 per share · 1,450% · Final dividend
- Dividend₹130.00 per share · 1,300% · Special special dividend
About Abbott India
Biotechnology & Drugs
Abbott India Limited is an India-based pharmaceutical company. The Company is involved in product development, manufacturing, sales, and customer service. It distributes products and solutions in multiple therapeutic categories, such as women's health, gastroenterology, cardiology, metabolic disorders and primary care. It operates in a single reportable business segment, which is Pharmaceuticals. The Company’s products include Arachitol Nano, Digeraft, Influvac, Colospa, Duphalac, Librax, Creon, Duphaston, Prothiaden, Cremaffin, Duvadilan, Thyronorm, Cremaffin Plus, Ganaton, Udiliv, Digene, Heptral, Vertin, Zolfresh, Citrosoda UTI, Digene Insta On The Go, Digeraft tablet, Duphaston OD, Pneumoshield 14, Prothiaden Neu, Vonefi, Levesam, and LOBATE M Skin Cream, among others. The Company sells its products through independent distributors primarily within India.
Key people
- Maithilee MistryChief Financial Officer
- Sangeeta Mukesh ShettyCompliance Officer, Company Secretary, Associate Director - Secretarial
- Kartik RajendranManaging Director, Executive Director
- Rajan KalantreDirector - Business Human Resources
- Jejoe KarankumarDirector - Medical Affairs
- Anushree KunhambuAssociate Director - New Product Introduction and Therapy Area Strategy
Company facts
- NSE symbolABBOTINDIA
- BSE code500488
- ISININE358A01014
- IndustryBiotechnology & Drugs
- IndexNIFTY 500
- Market cap₹57,457 Cr
- Revenue (FY26)₹6,929 Cr
- Net profit (FY26)₹1,552 Cr
In the News
Recent headlines about Abbott India — they open on Mint in a new tab.
- Trump's tariff policy: Abbott India, Ajanta Pharma to Alembic — pharma stocks crash up to 4%
Pharma stocks dipped on July 24 after President Trump announced a phased tariff plan for imported generic medicines, raising concerns for Indian exporters. Abbott India led losses at 3.69%, prompting fears over the future of American production and long-term impacts on stocks.
24 Jul 2026 · 4 min read · Mint ↗ - Gland Pharma to Biocon: Pharma stocks rally up to 27% in a month: Can they shield portfolio from US-Iran war-led risks?
The Nifty Pharma index has surged nearly 11% over the past month, significantly outperforming the Nifty 50, which declined 3.6% during the same period. On a year-to-date (YTD) basis, the Nifty Pharma index has gained 9.4%, while the benchmark Nifty 50 has fallen by an equal margin.
21 May 2026 · 3 min read · Mint ↗
Stock data comes from the exchange feed via our data provider and may be delayed. It is for information only and is not a recommendation to buy or sell. See all stocks →
Frequently Asked Questions
Abbott India (NSE: ABBOTINDIA) last traded at ₹26,930.00 on the NSE, up 0.12% (₹32.28) on the day, as of 24 Sep 2026, 9:59 AM. On the BSE it was ₹26,980.00. The day's range was ₹26,769.65 – ₹27,225.00.
Abbott India's 52-week high is ₹30,530.62 (25 Nov 2025) and its 52-week low is ₹25,049.28 (24 Apr 2026). At ₹26,930.00 the share is 11.8% below its high and 7.5% above its low.
Abbott India's market capitalisation is ₹57,457 Cr (₹57,457 Cr). It is part of the NIFTY 500 index.
Abbott India's P/E ratio (trailing 12 months) is 33.33. The sector average is 36.50, so investors pay 9% less for each rupee of its earnings than for the average company in its sector. Its earnings per share (TTM) are ₹759.88.
Abbott India shares are down 10.48% over the last year, down 6.78% so far this year, up 2.48% over 6 months, up 5.72% over 3 months. Over the last year the stock did 1.77% worse than the market.
In FY26 (year to Mar 2026), Abbott India reported revenue of ₹6,929 Cr (up 8.11% on the year before) and a net profit of ₹1,552 Cr. Earnings per share were ₹730.39.
Yes. Abbott India's latest dividend is ₹525.00 per share (5,250%, final dividend), with an ex-date of 24 Jul 2026. The dividend yield is 1.95%. It has paid 8 dividends in the records shown on this page.
Of 7 analysts covering Abbott India, 6 are bullish (4 strong buy, 2 buy), 1 say hold and 0 are bearish. The consensus is Strong Buy (average rating 1.57 on a scale where 1 is Strong Buy and 5 is Strong Sell). Analyst views are opinions, not a guarantee.
As of Jun 2026: Promoter 74.99%, FII 0.38%, MF 7.44%, Other 17.19%.
Abbott India's listed peers in Biotechnology & Drugs include Sun Pharmaceutical Industries, Divi's Laboratories, Torrent Pharmaceuticals, Cipla, Zydus Lifesciences. By market capitalisation it ranks #6 of 6 in this group.